Market revenue in 2023 | USD 702.4 million |
Market revenue in 2030 | USD 1,332.1 million |
Growth rate | 9.6% (CAGR from 2023 to 2030) |
Largest segment | Medical |
Fastest growing segment | Dental |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Dental, Medical, Biosensors, Consumer/Personal Product Testing, Bioinks, Food and Animal Product |
Key market players worldwide | EnvisionTEC, Organovo Holdings Inc, 3D Systems Corp, Inventia Life, Poietis, Vivax Bio, Cyfuse Biomedical, Cellink, Regemat 3D |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to 3d bioprinting market will help companies and investors design strategic landscapes.
Medical was the largest segment with a revenue share of 38.51% in 2023. Horizon Databook has segmented the North America 3d bioprinting market based on dental, medical, biosensors, consumer/personal product testing, bioinks, food and animal product covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. FDA does not directly regulate 3D printers; its regulatory focus is on the manufacturing process and the output of 3D printers if that output qualifies as a medical device. The Center for Devices and Radiological Health (CDRH) has addressed regulating 3D-printed medical products through various means, including public forums, formal guidance, and presentations.
It is important to note that the FDA's guidance on this matter is subject to change due to the evolving nature of the technology. The regulatory pathway for 3D bio-printed products depends on their intended use, risk classification, and specific characteristics. Furthermore, the FDA is refining its regulatory framework for point-of-care 3D printing of medical devices (3DPOC).
The potential advantages of this approach include enhancements in patient care, cost reduction, and expanded accessibility to medical products. However, the FDA's current regulatory framework for 3DPOC is not clear. The FDA has not yet issued any specific guidance on how 3DPOC devices should be regulated.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America 3d bioprinting market , including forecasts for subscribers. This continent databook contains high-level insights into North America 3d bioprinting market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account